Company TaiMed Biologics Inc.

Equities

4147

TW0004147004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for TaiMed Biologics Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
83 ^TWD	+0.61%		-0.12%	+1.22%

Mar. 20	TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 13	Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	CI

TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.

TWD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Antibodies 100.0 %	563	100.0 %	492	100.0 %	-12.65%

TWD in Million	2022	Weight	2023	Weight	Delta
Taiwan 100.0 %	563	100.0 %	492	100.0 %	-12.65%

Managers	Title	Age	Since
Chin-Ming Chang CEO	Chief Executive Officer	-	-
I Cheng Chen DFI	Director of Finance/CFO	-	08-05-31
Nien Yuan Chang CHM	Chairman	-	09-06-11
YingAn Lai LAW	General Counsel	-	-
Jason Mao PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Chi-Chuan Chen BRD	Director/Board Member	66	-
Ta Meng Tseng BRD	Director/Board Member	66	18-09-06
Nien Yuan Chang CHM	Chairman	-	09-06-11
Howard Lee BRD	Director/Board Member	62	17-05-25
Tien Chieh Li BRD	Director/Board Member	-	21-02-23
Shih Chia Lin BRD	Director/Board Member	-	-
Gwo-Fong Lin BRD	Director/Board Member	68	20-06-03
Chin Ting Chiu BRD	Director/Board Member	-	-
Hui Chuan Chang BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	253,009,730	166,588,730 ( 65.84 %)	0	65.84 %

Name	Equities	%	Valuation
National Development Fund of The Executive Yuan 15.06 %	40,512,012	15.06 %	111 M NT$
Ruen Hua Dyeing & Weaving Co., Ltd. 6.832 %	18,379,028	6.832 %	50 M NT$
RUENTEX DEVELOPMENT CO.,LTD. 3.906 %	10,507,849	3.906 %	29 M NT$
RUENTEX INDUSTRIES LTD. 3.870 %	10,410,455	3.870 %	28 M NT$
Zhongze Yao 1.321 %	3,552,867	1.321 %	10 M NT$
Mihhao Industrial Co. Ltd. 0.8346 %	2,245,144	0.8346 %	6 M NT$
Chi Sheng Lin 0.7695 %	2,069,991	0.7695 %	6 M NT$
Yi Tai Investment Co. Ltd. (Ruentex) 0.6132 %	1,649,439	0.6132 %	5 M NT$
Capital Investment Trust Corp. 0.4149 %	1,115,975	0.4149 %	3 M NT$
Nien Yuan Chang 0.3351 %	901,313	0.3351 %	2 M NT$

TaiMed Biologics, Inc.

3rd Floor No. 607 Ruiguang Road

114 92, Taipei

http://www.taimedbiologics.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

83 TWD

Average target price

133.7 TWD

Spread / Average Target

+61.07%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TAIMED BIOLOGICS INC.	+1.22%	644M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs